Vivo Opportunity Fund Holdings, L.P. - 29 Sep 2025 SCHEDULE 13G Report for SAB Biotherapeutics, Inc. Common Stock, par value $0.0001 per share (SABS)

Filing Manager
Vivo Opportunity Fund Holdings, L.P.
Reporting Manager
Vivo Opportunity Fund Holdings, L.P.
Security
SAB Biotherapeutics, Inc. Common Stock, par value $0.0001 per share
Symbol
SABS
Shares outstanding
259,569,570 shares
Disclosed Ownership
25,931,000 shares
Ownership
10%
Form type
SCHEDULE 13G
Filing time
03 Oct 2025, 16:30:36 UTC
Date of event
29 Sep 2025
SEC
View on sec.gov

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Vivo Opportunity Fund Holdings, L.P. 10% 25,931,000 25,931,000 0 /s/ Kevin Dai Kevin Dai/Managing Member of General Partner
Vivo Opportunity, LLC 10% 25,931,000 25,931,000 0 /s/ Kevin Dai Kevin Dai/Managing Member
Vivo Opportunity Cayman Fund, L.P. 10% 2,619,000 2,619,000 0 /s/ Kevin Dai Kevin Dai/Managing Member of General Partner
Vivo Opportunity Cayman, LLC 10% 2,619,000 2,619,000 0 /s/ Kevin Dai Kevin Dai/Managing Member